RYM:NZXRyman Healthcare Ltd. Analysis

Technical outlook: RYM is trading at $17.69, just above its 20‑day SMA (≈$17.39) but well below the 50‑day (≈$18.28) and 200‑day (≈$27.24) averages, signaling a bearish bias. The RSI sits at ~49, indicating neutral momentum, while the MACD histogram is positive and the signal line label is "bullish," suggesting limited short‑term upside. Volume is on an increasing trend, and the price is hovering near the identified support at $14.75 with resistance around $21.12.
Fundamental outlook: The company reports flat revenue (~$17.3 M) with a healthy gross margin (~59%) but severe operating losses (‑33% operating margin) and a net loss per share of $‑17.42. Debt is overwhelming ($80.6 M) versus cash ($32.2 M), yielding a debt‑to‑equity ratio above 600, and both operating and free cash flow are deeply negative. The stock’s volatility is extremely high (~100% 30‑day) and historical drawdowns have reached ‑69%, underscoring substantial downside risk. No dividend is paid, and the valuation metrics (P/B ≈2.9, P/S ≈2.2) appear stretched given the deteriorating earnings profile.